IV Fluid Supply Updates

Research News at Hollings

Facebook icon Twitter icon Instagram icon LinkedIn logo icon

Clinical trial of purified CAR-T cell therapy awarded $3.2M NCI grant to expand

a group of people stand in a hospital hallway chatting

With the first two patients in a clinical trial testing purified CAR-T cells both showing complete remission, the National Cancer Institute has stepped forward with $3.2 million in funding to expand the trial.

Brian Hess, M.D., and Shikhar Mehrotra, Ph.D., have partnered on the trial, which is testing a new patented variation of CAR-T cell therapy that the researchers hope will have longer-lasting results with fewer side effects.

Learn about the trial

 

Adam Fox, M.D., pulmonologist and researcher, poses in a hallway at Hollings Cancer Center

Reflex Biomarker Testing

Too many lung cancer patients don't get all the biomarker testing they should have before beginning treatment. Dr. Adam Fox wants to change that.

portrait of immunologist Silvia Guglietta in her lab at Hollings Cancer Center

Unlocking Immunotherapy

A Hollings immunologist will use an American Cancer Society Research Scholar Grant to study ways to make colorectal cancer more susceptible to immunotherapy.

image of the Hollings Cancer Center building with its preserved 1913 facade of columns and brick

P. gingivalis and Cancer

An MUSC Hollings Cancer Center team describes how the bacteria Porphyromonas gingivalis connects to chemotherapy resistance.

Dr. Christina Voelkel-Johnson

Monster Cancer Cells

Polyploid giant cancer cells, which are monstrously oversized and contain multiple nuclei, could be culprits in disease recurrence after cancer therapy.
two women and a man, all researchers in the Barnoud Lab at Hollings Cancer Center, pose in the lab

Targeting Pancreatic Cancer

A new study from Hollings researchers suggests a dual approach for targeting pancreatic cancer.

a man and woman pose in front of a wall bookshelf

Medication to Quit E-Cigs

A new study is the first in the U.S. to show that an available generic drug could help people stop using e-cigarettes.

Man in a white lab coat smiles seated in a lab.

Cancer Vaccine

Leukogene Therapeutics Inc. introduces a promising therapy to treat multiple cancers and hopes to become flagship entity for MUSC’s innovation ecosystem.
HPV cancers researcher Ashish Deshmukh poses in a garden

Geographic Risk Disparities

For people with HIV, the risk of anal cancer varies significantly depending on the region of the country where they live.

T cells attacking cancer cells. Image by Meletios Verras. Licensed from istockphoto.com

Improving Cancer Immunotherapy

Hollings researchers use patented technology to improve immunotherapy by prolonging survival of cancer-fighting T-cells.